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patient with autopsy confirmed Alzheimer disease (AD)
and onset age of 50 years. Subsequently, we sequenced
PLD3 in a Belgian early-onset Alzheimer disease (EOAD)
patient (N = 261) and control (N = 319) cohort, as well
as in European EOAD patients (N = 946) and control
individuals (N = 1,209) ascertained in different European
countries. Overall, we identified 22 rare variants with a
minor allele frequency <1%, 20 missense and two splicing
mutations. Burden analysis did not provide significant ev-
idence for an enrichment of rare PLD3 variants in EOAD
patients in any of the patient/control cohorts. Also, meta-
analysis of the PLD3 data, including a published dataset
of a German EOAD cohort, was not significant (P = 0.43;
OR = 1.53, 95% CI 0.60–3.31). Consequently, our data
do not support a role for PLD3 rare variants in the ge-
netic etiology of EOAD in European EOAD patients. Our
data corroborate the negative replication data obtained in
LOAD studies and therefore a genetic role of PLD3 in
AD remains to be demonstrated.
Hum Mutat 36:1226–1235, 2015. Published 2015 Wiley Period-
icals, Inc.∗
KEY WORDS: Alzheimer dementia; EOAD; PLD3; next-
generation sequencing; rare variants; meta-analysis
Introduction
Whole-exome sequencing (WES) in familial late-onset Alzheimer
disease (LOAD) patients identified phospholipase D3 (PLD3; MIM
#615698) as a new risk gene, with risk variants doubling risk to
develop LOAD [Cruchaga et al., 2014]. Typically, phospholipase D
(PLD) hydrolyzes the phosphodiester bond of phosphatidylcholine
to produce phosphatidic acid (PA) and free choline. PA is an intra-
cellular lipid mediator of many biological functions attributed to
PLD, including calcium mobilization, secretion, vesicle trafficking,
glucose transport, mitogenesis, and apoptosis [Jang et al., 2008].
A functional link between the PLDs and AD, particularly PLD1,
has been previously established. PLD1 was shown to interact with
presenilin 1 (PSEN1), to antagonize the PSEN1-mediated cleavage
of βAPP [Cai et al., 2006a] and to affect its intracellular traffick-
ing [Cai et al., 2006b]. For PLD3, the canonical activity had not
yet been identified [Munck et al., 2005], but Cruchaga et al. (2014)
demonstrated an inverse correlation between PLD3 and amyloid-β
in vitro, proposing a role for PLD3 in APP processing. The PLD3
variant, p.A442, was associated with reduced PLD3 mRNA expres-
sion, corroborating the proposed role of PLD3 in LOAD [Cruchaga
et al., 2014]. Another variant, p.V232M, was associated with both
disease risk and earlier onset age [Cruchaga et al., 2014], suggest-
ing a possible role for PLD3 variants in risk for early-onset AD
(EOAD).
We analyzed available whole-genome-sequencing (WGS) data
of 20 AD patients with early onset of disease and WES data of
five probands diagnosed with autosomal dominant inherited AD,
for genetic variation in known causal and risk genes reported for
AD. We identified one missense mutation in PLD3 in a familial
EOAD patient with autopsy confirmed AD and onset of disease
at the age of 50 years. This finding prompted us to screen PLD3
in cohorts of Belgian EOAD patients and matched control indi-
viduals. No evidence for a genetic risk association was obtained.
Next, we replicated our PLD3 findings in four European EOAD pa-
tient/control cohorts ascertained within the European Early-Onset
Dementia consortium [van der Zee et al., 2013; van der Zee et al.,
2014; Cuyvers et al., 2015]. While our studies were in progress,
four publications provided evidence that the initial PLD3 risk as-
sociation, obtained in a family-based study, could not be replicated
in independently ascertained LOAD patient/control cohorts [Lam-
bert et al., 2015; van der Lee et al., 2015; Heilmann et al., 2015;
Hooli et al., 2015], questioning a role for rare PLD3 variants in AD
risk.
Methods
Belgian Patient/Control Cohorts
The EOAD patient group consisted of unrelated AD patients
(n = 286), aged 70 years at inclusion, of which n = 123 (43%)
were diagnosed at age65 years. The EOAD patients were selected
from a larger AD patient group sampled within a prospective study
of Belgian dementia patients at the Neurology Department and
Memory Clinic of the Hospital Network Antwerp (ZNA) Middel-
heim and Hoge Beuken, (P.P.D.D. and S.E.) [Engelborghs et al.,
2003; Engelborghs et al., 2006] and the Department of Neurol-
ogy and the Memory Clinic of the University Hospitals of Leuven,
Leuven, (R.V. and M.V.) [Bettens et al., 2010], as well as through
the neurology centers of the clinical partners within the Belgian
Neurology (BELNEU) consortium. In the EOAD patient cohort,
average onset age was 63.6 ± 6.3 years (range 37–70; in addition,
two autosomal dominant AD probands had a later onset age of
76 and 77 years, respectively), 58% were women, and 37 of the
patients received a definite diagnosis of AD at autopsy. Consen-
sus diagnosis of possible, probable or definite AD was given by at
least two neurologists based on the National Institute of Neurolog-
ical and Communicative Disorders and Stroke (NINCDS) and the
Alzheimer’sDisease andRelatedDisorders Association (ADRDA) or
the National Institute on Aging-Alzheimer’s Association (NIA-AA)
diagnostic criteria [McKhann et al., 1984;McKhann et al., 2011;Hy-
man et al., 2012]. Each AD patient underwent a neuropsychological
examination, including Mini-Mental State Examination (MMSE)
[Folstein et al., 1975] and structural imaging, and a subset of pa-
tients was also examined by functional neuroimaging [Bettens et al.,
2010].
The Flanders-Belgian control cohort consisted of 319 unrelated
older individuals with a mean age at inclusion of 68.7 ± 12.2 years
and 64% women. Subjective memory complaints and neurologi-
cal or psychiatric antecedents as well as a familial history of neu-
rodegeneration were ruled out by means of an interview. Cognitive
screening was performed using the MMSE (inclusion cutoff score
26) [Folstein et al., 1975] or the Montreal Cognitive Assessment
(inclusion cutoff score 25), a 30-point test known to be sensitive
for Mild Cognitive Impairment (MCI) and early AD [Nasreddine
et al., 2005]. The majority (n = 233) of the control individuals con-
sisted of community-dwelling volunteers and spouses of patients,
who were recruited in the hospital upon neurological examination
of their affected spouse.
All participants and/or their legal guardian in case of dementia
patients, signed a written informed consent form for participation
in clinical and genetic studies. The clinical study protocols and the
informed consent forms for patients and control individuals were
approved by the Ethics Committee of the respective hospitals and/or
universities involved in the sampling in Belgium through partners of
the BELNEU consortium. The genetic study protocol was approved
by the Ethics Committee of the University of Antwerp and the
University Hospital of Antwerp, Belgium.
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EU Patient/Control Cohorts
EOAD patients and control individuals were ascertained by EU
partners in the EU EOD consortium [van der Zee et al., 2013; van
der Zee et al., 2014; Cuyvers et al., 2015]. DNA, medical, and de-
mographic information were available of 946 EOAD patients with
onset age of 65 years. For this study, the individual countries
contributed 313 (Spain), 108 (Portugal), 194 (Italy), 172 (Sweden),
98 (Germany), 54 (Greece), and seven (Czech Republic) EOAD
patients. The German patient cohort overlaps in part with the
EOAD cohort screened for PLD3 variations by Schulte and col-
leagues [Schulte et al., 2015]. The EOAD patients were diagnosed
following the NINCDS-ADRDA International Working Group cri-
teria [McKhann et al., 1984; McKhann et al., 2011]. Pathological
diagnosis of definite AD patients was based on current diagnostic
criteria [Montine et al., 2012]. A definite AD diagnosis was available
for 40 patients from Spain, two patients from Portugal, five patients
from Italy, twopatients fromSweden, and seven patients fromCzech
Republic.
The total EUcontrol groupconsistedof 1,209persons contributed
by partnering countries Spain (303), Portugal (126), Italy (428),
Sweden (345), and Czech Republic (7). Control persons had normal
cognition based on MMSE (inclusion cutoff score 26). All EU
participants signed informed consent forms that were approved by
the ethics committee of the local hospitals or sampling sites.
PLD3 Variation in WGS and WES data of Belgian EOAD
Patients
For WGS studies, we had selected 20 patients from the EOAD
cohort with an early-onset age (mean 56.7 years ± 6.6 years; range
37–65 years), of whom 15 were negative for the ε4 allele of the
apolipoprotein E gene (APOE). An additional five probands of au-
tosomal dominant families (mean 61.4 years; range 50–77 years)
were selected for WES. For all 25 patients, pathological mutations
in APP, PSEN1, and PSEN2 were excluded.
WGS was outsourced to Complete Genomics (Mountain View,
CA) making use of unchained combinatorial probe anchor liga-
tion chemistry on self-assembling DNA nanoballs [Drmanac et al.,
2010]. Raw data reads were assembled to the reference genome (Na-
tional Center for Biotechnology Information build 36 or Genome
Reference Consortium Human Build 37/hg19 (GRCh37/hg19)).
Sequencing alignment and variant calling were performed at
Complete Genomics (Complete Genomics, whereas data annota-
tion and analysis were performed by us with the GenomeComb
package [Reumers et al., 2012]. WES data were generated with
various enrichment kits and sequencing was performed on the
Illumina
R©
NextSeq (http://www.illumina.com) or on the Applied
Biosystems SOLiD 5500 (http://www.solid.appliedbiosystems.com)
systems. Sequence manipulation and variants calling from the
Illumina
R©
NextSeq data were performed with GenomeComb
[Reumers et al., 2012], which integrates the pipeline for NGS
data analysis. Sequencing data obtained from the SOLiD 5500 sys-
tem where analyzed using LifeScopeTM Genomic Analysis Soft-
ware (http://www.lifetechnologies.com/lifescope), annotated and
analyzed using the GenomeComb package [Reumers et al., 2012].
Sequence data of PLD3 (RefSeq NM 001031696.3) coding exons
(including intron-exon boundaries) were extracted from the anno-
tated WGS and WES data. For all sequenced samples, at least 95%
of the coding DNA sequence (CDS) of PLD3 was covered 20×.
Coding and splice variants with a coverage20× and aminor allele
frequency (MAF) lower than 1% in the Exome Variant Server (EVS;
http://evs.gs.washington.edu/EVS/) were selected.
PLD3 Sequencing in EOAD Patient/Control Cohorts
In the Belgian cohort, the CDS of PLD3 (RefSeq
NM 001031696.3) was analyzed by Sanger sequencing (BigDye Ter-
minator Cycle Sequencing kit v3.1 on the ABI 3730 DNA Ana-
lyzer (both Applied Biosystems
R©
, Waltham, Massachusetts, USA).
Sequences were analyzed for genetic variations using SeqManII
(DNASTAR, Madison, WI) and/or novoSNP [Weckx et al., 2005]
software packages. All DNAs included in the study were successfully
screened for at least 85% of the CDS of PLD3.
To screen the EU EOAD cohorts, we designed an amplicon-based
gene assay for massive parallel sequencing of all coding exons of
PLD3. PLD3 exonic regions were taken from Gencode human gene
annotation set release v19 [Harrow et al., 2012]. A minimum of
15 nt intronic sequence flanking each exon was included to cover
splice sites. Target regions larger than 500 nt in size were divided
into contiguous segments of less than 500 nt to anticipate sequence
read coverage in subsequent massive parallel sequencing experi-
ments. Adjacent target regions located within a 500 bp segment
were combined to form a single target region. PCR Primers flank-
ing each target were designed using mPCR (Multiplicom N.V.,
Niel, Belgium), a software tool to design multiplex PCR panels
for specific and uniform target amplification, built around the
Primer3 program [Koressaar and Remm, 2007]. Together, all targets
were covered by 19 amplicons in three multiplex PCR reactions.
Target-specific primer sequences were extended with tag sequences
(5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-Fwd and
5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-Rev) for
subsequent indexing and sequencing. First, optimal annealing tem-
perature and relative amounts of individual PCR primers were op-
timized for uniform amplification of each target in the multiplex
reaction. Then, multiplex PCR reactions were carried out on 20 ng
genomiphied DNA (Illustra GenomiPhi V2; Thermo Fisher Scien-
tific Inc., Waltham, Massachusetts, USA). The amplification quality
and efficiency of each reaction was verified by fragment analysis on
an ABI 3730 automated sequencer, and the amplification products
of all multiplex PCR reactions of each individual were pooled aim-
ing at equimolar representation of the amplicons in the mixture.
Per-individual indexing was performed using the Nextera indexing
system (Illumina
R©
) allowing the pooling of up to 1,536 distinct in-
dex combinations. After indexing, amplicons were pooled in three
separate sequencing libraries. Massive parallel sequencing was per-
formed on a MiSeq sequencer (Illumina
R©
) using V2 chemistry to
generate 2× 250 paired-end sequencing reads. After sample demul-
tiplexing, sequence reads were mapped using the Burrows-Wheeler
Aligner [Li andDurbin, 2009; Li andDurbin, 2010] to aminigenome
consisting of the combined amplicon sequences extracted from the
human genome reference sequence hg19. Sequence variants were
called using the Genome Analysis Toolkit [McKenna et al., 2010;
DePristo et al., 2011]and annotated using the GenomeComb vari-
ant annotation pipeline [Reumers et al., 2012].
Variantswith a read depth below15×, withGenoqual value below
99 or with an imbalanced wild-type/variant read depth (cutoff > 4)
were considered false calls. All remaining rare (MAF < 1%) variants,
predicted to affect protein sequence and splicing variants, were val-
idated on genomic DNA by Sanger sequencing. We also selected
the silent p.A442 variant because of the previous reported AD risk
association [Cruchaga et al., 2014], and included it in downstream
statistical analysis.
The variants reported are based on the RefSeq NM 001031696.3.
The nucleotide positions refer to the cDNA sequence and the nu-
cleotide numbering uses +1 as the ATG translation initiation codon
in the reference sequence, with the initiation codon as codon 1. The
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variants identified in this study have been submitted to the Leiden
Open Variation Database (LOVD) Locus Specific Database (LSDB)
(http://databases.lovd.nl/shared/genes/PLD3).
Statistical Analyses
A rare variant (MAF < 1%) burden analysis was performed by col-
lapsing of rare variant alleles and comparing the overall frequency
of rare variant alleles between patients and control individuals using
χ 2 statistics. Odds ratios (OR) and 95% confidence intervals were
computed. A two-sided P value <0.05 was considered significant.
Fixed effect (Mantel–Haenszel) meta-analysis was performed based
on the allelic data of the Belgian and EU EOAD cohorts. Because
of too small sample size or lack of a matched control group, we
did not include the Czech, German, and Greek cohorts in the as-
sociation analysis. Meta-analysis was performed on the PLD3 data
obtained in the Belgian, Spanish, Portuguese, Italian, and Swedish
patient/control cohorts plus the one published German study of
PLD3 in EOAD [Schulte et al., 2015]. Mantel–Haenszel summary
P value, OR, Higgins I2, and Cochran’s Q test for het-
erogeneity were computed in R using the library epiR,
version 0.9–62.
Characterization of PLD3 Splicing Variants
Bioinformatic prediction analysis of splicing variants was
performed using both FSPLICE 1.0 (http://www.softberry.com/;
Softberry, Inc., Mount Kisco, NY, USA) and NNSPLICE 0.9 (http://
www.fruitfly.org/seq_tools/splice.html) [Reese et al., 1997]. Both
programs search for splicing sites in the input sequence. The analy-
sis was performed on both wild-type and mutated sequences using
both tools and the comparison between the outputs was performed
to identify differences in the splicing sites identification (Supporting
Information).
Total RNA was extracted from lymphoblast cell lines using the
RiboPureTM kit, Ambion
R©
(Life TechnologiesTM, Waltham, Mas-
sachusetts, USA) followed by DNase treatment, performed using
Ambion
R©
TURBODNA-freeTM kit (Life TechnologiesTM). Comple-
mentaryDNAwas prepared from the total RNA, using SuperScript
R©
III First-Strand Synthesis System for RT-PCR, InvitrogenTM (Life
TechnologiesTM) with random hexamer primers including a con-
trol reaction without retro-transcriptase enzyme. cDNA amplifica-
tion was carried out using Titanium
R©
Taq DNA Polymerase (Clon-
tech Laboratories, Inc., Mountain View, CA, USA). PCR prod-
uct agarose gel band extraction was performed using QIAquick
Gel Extraction Kit (http://www.qiagen.com) following the manu-
facturer guidelines. The purified amplification products were se-
quenced (BigDye Terminator Cycle Sequencing kit v3.1; Applied
Biosystems
R©
) or cloned into pCRTM2.1-TOPO
R©
vector follow-
ing manufacturer instructions and the purified vector was se-
quenced and analyzed on an ABI 3730 DNA Analyzer (Applied
Biosystems
R©
). Sequence analysis was performed using SeqManII
(DNASTAR).
Results
PLD3 Variants in the Belgian EOAD Patient/Control Cohort
Analysis of theWGSdata of 20 unrelated EOADpatients andWES
data of five probands of autosomal dominant AD families revealed
one rare PLD3 variant, p.N284S, in a familial EOAD patient with
an onset age of 50 years and an APOE ε3ε3 genotype. Review of
the clinical course of the disease in the carrier showed no unusual
characteristics. The amyloid β T-tau and P-tau biomarker profile
in cerebrospinal fluid was compatible with AD, and autopsy after a
disease duration of 7 years confirmed the diagnosis of AD (Braak
and Braak stage V-VI, Montine classification A3B3C3). Based on
heteroanamnesis, both parents had late-onset dementia >90 years
and a paternal uncle had cognitive impairment at younger age.
DNA of family members was not available for genetic testing of
PLD3.
The sequencing of PLD3 in the 261 remaining Belgian patients,
identified four missense mutations and one splicing variation in
eight patients (Fig. 1), resulting in a cumulative rare variant fre-
quency in Belgian EOAD patients of 3.15% (nine out of 286)
(Table 1). This included one missense, p.P173S, and one splicing
variant, c.1285+1G>A (p.K396Efs∗6), that had not yet been re-
ported. In 10 control individuals, we observed seven different non-
synonymous mutations (10 out of 319, 3.13%) of which three were
new (Table 1). Of the reported LOAD-associated variants [Cruchaga
et al., 2014], we identified p.V232M in one patient and four control
persons (P = 0.2). The p.A442 variant was observed in seven patients
(seven out of 286, 2.4%) and 10 control individuals (10 out of 319,
3.13%) (P = 0.6). Rare variant gene-based burden analysis did not
show a significant enrichment of PLD3 rare variant alleles in AD
patients compared with control individuals (P = 1.0, relative risk
(OR) = 1.00, 95% CI = 0.40–2.49).
PLD3 Replication Analysis in the EU Cohorts
To replicate our finding and increase statistical power, we in-
vestigated PLD3 in 946 EOAD patients and 1,209 age- and origin-
matched control individuals ascertained by partners of the EU EOD
consortium in Spain, Portugal, Italy, Sweden, Germany, Greece,
and Czech Republic. In the overall patient/control cohort, we
identified 15 genetic variants with a MAF <0.01, 14 missense
and one splicing variant (Fig. 1), in a total of 50 participants
of which 31 (62%) patients. Six variants—p.V159M, p.R162C,
p.A175G, p.R188C, p.A293V, and p.T426A—were present in pa-
tients only, and four variants—p.R222H, p.E249G, c.1019+2T>A
(p.S294Vfs∗6), and p.G429R, in control persons only (Table 1). The
LOAD-associated p.A442 variant was found in 45 persons of which
24 (53.3%) patients.One control individual fromSpain carried both
the p.N284S and the p.A442 variant.
Rare variant gene burden analysis did not show an enrichment
for rare variants in patients when comparing missense and splicing
variants in patients against control individuals in separate cohorts
nor when the different patient/control cohorts of Belgium, Spain,
Portugal, Italy, and Sweden were pooled in a meta-analysis includ-
ing one published German study on EOAD (Schulte et al., 2015)
(P = 0.43; summary OR = 1.53, 95% CI 0.60–3.31) (Table 2). The
LOAD-associated p.V232M variant was found in the Spanish pa-
tient/control cohort in one patient (one out of 313, 0.32%) and
one control (one out of 303, 0.33%) (P = 0.98), in the Swedish pa-
tient/control cohort in two patients (two out of 172, 1.16%) and
one control (one out of 345, 0.29%) (P = 0.22), in the Italian pa-
tient/control cohort in four Italian control individuals (four out of
428, 0.93%) and in two of the German patients (Table 1). Meta-
analysis did not show association of p.V232M with disease status
(P = 0.44; OR = 0.79, 95% CI 0.07–3.11). Similarly, the p.A442
variant did not show association across cohorts nor when meta-
analysis was performed (P = 0.89; OR = 1.13, 95% CI 0.40–2.22)
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Figure 1. Location of PLD3 variants. Schematic representation of rare missense and splicing variants identified in the PLD3 (RefSeq
NM_001031696.3), in the Belgian and EU EOAD cohorts. For completeness, the p.A442 variant is also reported. Variations in red are observed
in patients-only, in blue in control persons-only and in black those identified in both patients and control individuals (Table 1). Variants marked with
an asterisk (∗) were previously reported by Cruchaga et al. (2014). The exon numbering follows the RefSeq NM_001031696.3.
Table 2. Meta-Analysis of PLD3 Rare Variants
Total alleles (N) Missense and splicing variants p.A442 variant
Country AD C AD (MAF%) C (MAF%) OR [95% CI] AD (MAF%) C (MAF%) OR [95% CI]
Belgium 572 638 9 (1.57) 10 (1.57) 1.00 [0.40–2.49] 7 (1.22) 10 (1.57) 0.78 [0.29–2.06]
Spain 626 606 9 (1.44) 4 (0.66) 2.20 [0.67–7.17] 11 (1.76) 4 (0.66) 2.69 [0.85–8.50]
Portugal 216 252 4 (1.85) 1 (0.40) 4.74 [0.53–42.69] 2 (0.93) 1 (0.40) 2.35 [0.21–26.05]
Sweden 344 690 4 (1.16) 5 (0.72) 1.61 [0.43–6.04] 3 (0.87) 9 (1.30) 0.67 [0.18–2.47]
Italy 388 856 5 (1.29) 9 (1.05) 1.23 [0.41–3.70] 1 (0.26) 6 (0.70) 0.37 [0.04–3.05]
Schulte et al. (2015) 278 2,912 3 (1.08) 18 (0.62) 1.75 [0.51–5.99] 5 (1.80) 39 (1.34) 1.35 [0.53–3.45]
Summary 2,424 5,954 34 (1.40) 47 (0.79) 1.53 [0.60–3.31] 29 (1.20) 69 (1.16) 1.13 [0.40–2.22]
PMH value 0.43 0.89
Q P value 0.78 0.36
I2 (%) 0 8.89
Meta-analysis was performed on the five patient/control cohorts screened in this study together with the published data on EOAD [Schulte et al., 2015]. Rare (MAF <1%)
non-synonymous and splicing alleles were included in the rare variant gene burden analysis. Total allele counts and frequencies of rare non-synonymous and splicing variants
as well as the p.A442 variant (c.1326G>A, RefSeq NM_001031696.3) identified in AD patients and control (C) individuals are shown. The P value is given for fixed-effect
Mantel–Haenszel test (pMH) and Higgins I2 (%) and Cochran’s Q test (P value) for heterogeneity are shown for the meta-analysis.
(Table 2). Because of the functional effect of the p.A442 variant on
splicing [Cruchaga et al., 2014], we included this variant together
with the missense and the splicing variants in the gene burden and
meta-analysis. Also in this case, we did not identify association with
disease status in the meta-analysis (P = 0.57; OR = 1.32, 95% CI
0.65–2.20) (Fig. 2). In the Spanish patient/control cohort, however,
a gene burden positive association was observed when the p.A442
variant was included (P = 0.03; OR 2.47, 95%CI 1.07–5.64) (Fig. 2).
The investigated cohorts did not show evidence of heterogeneity
(I2 range 0%–21.08%; Q P value > 0.27). Random-effects meta-
analysis, according to DerSimonian and Laird, confirmed absence
of association (Supporting Information).
PLD3 Splicing Variants Lead to Exon Skipping
Two carriers of a PLD3 splicing variant were identified:
c.1019+2T>A (hg19, chromosome 19, g.40880529) in a Swedish
control individual aged 61 years at inclusion, and c.1285+1G>A
(hg19, chromosome 19, g.40883793) in a Belgian AD patient with
onset age 69 years. Two independent software tools predicted that
the c.1019+2T>A variant is likely to abolish the canonical splice
donor site of exon 10 (alias exon 8 in [Cruchaga et al., 2014]). This
will cause skipping of exon 10 and the predicted introduction of a
premature stop codon after 298 amino acids (p.S294Vfs∗6). Cells
were not available to validate whether the mutant transcript is de-
graded by the nonsense-medicated mRNA decay (NMD) control
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Figure 2. Forest plot for meta-analysis of rare variant association.
Forest plot for meta-analysis of the rare missense and splicing variants,
and the p.A442 variant. Fixed-effects meta-analysis is based on raw
allelic data. Five different countries (Belgium, Spain, Portugal, Sweden,
and Italy) in addition to the German cohort published by Schulte et al.
(2015), are included in the statistical analysis. Summary statistics, fixed-
effectsPvalue (PMH-value)andodds ratio (OR) including95%confidence
interval (CI) is given in the figure. Evidence of heterogeneity is tested
using Cochran’s Q test (P value) and the Higgins I2 statistics (%).
system. The c.1285+1G>A variant is located at the first base of the
canonical splice donor site of exon 12 (alias exon 10) and is pre-
dicted to abolish the donor splice site of exon 12, causing out-frame
skipping of exon 12 and the premature introduction of a stop codon
in exon 13, the last exon of PLD3, leading to the predicted protein
change p.K396Efs∗20. We produced cDNA from lymphoblast cells
of the patient carrier and confirmed exon 12 skipping by Sanger
sequencing and agarose gel electrophoresis (Fig. 3). In addition to
the two expected alleles, we observed a third band that was about
100 bp longer than the normal allele. This longer band was best vis-
ible after amplification of exon 11 to 3′UTR PLD3 cDNA fragment
even though also detectable when amplifying the full-length PLD3
cDNA. In the same experiment, it was also faintly visible in control
individuals (Fig. 3). Sequencing of the bands extracted from the
4% agarose gel of the c.1285+1G>A carrier confirmed the absence
of exon 12 in the shorter fragment (lower band) and the wild-type
sequence in the normal fragment (middle band). The sequence of
the longer fragment, which was cloned in a sequencing vector af-
ter extraction form the agarose gel, indicated the presence of the
intron 12 sequence and the c.1285+1G>A variation as the result of
intron retention in the absence of an active exon 12 splice donor site
(Fig. 3).
Discussion
Rare variants in PLD3 have been associated with an increased risk
of developing LOAD in one study [Cruchaga et al., 2014]. More-
over, in that study, themissense variant p.V232Mwas also associated
with onset age and the silent variant, p.A442, was associated with
LOAD risk and lower levels of both PLD3 total mRNA and of PLD3
exon 13 (alias exon 11)-containing transcripts. The p.A442 variant
was predicted to affect alternative splicing by changing the consen-
sus sequence of an exonic splicing enhancer binding site [Cruchaga
et al., 2014]. PLD3 is highly expressed in hippocampus and cerebral
cortex, critical regions for AD pathology, and it was shown that
senile plaques in the frontal cortex containing dystrophic neurites
have intense PLD3 immunoreactivity [Satoh et al., 2014]. In case of
decreased PLD3 protein expression, APP processing is altered and
more extensive amyloid-β pathology is detected [Cruchaga et al.,
2014]. We investigated, in a first stage, the WGS and WES data of
a selection of high genetic load Belgian EOAD patients, collected
and prioritized for their potential of harboring high penetrant, dis-
ruptive variants responsible for the onset of AD at younger age.
The identification of the p.N284S variant in PLD3 in one familial
EOAD patient with an onset age of 50 years and an autopsy di-
agnosis of AD, prompted us to analyze a Belgian cohort of EOAD
patients (N = 261) without a mutation in the three AD genes APP,
PSEN1, and PSEN2, and matched control individuals. Although we
did identify additional genetic variations in PLD3, both new and
reported ones, the rare variant burden analysis was not significant.
To replicate this negative finding, we analyzed patient/control co-
horts of different European countries ascertained by partners from
the European EOD consortium, in total, 946 EOAD patients and
1,209 control individuals. In total, we identified 22 rare variants
with a MAF <1%, 20 missense and two splicing variants. Nonethe-
less, we did not identify an enrichment of rare variants in patients
compared with control individuals, neither when we investigated
gene burden or single variants that were previously associated with
LOAD per country, nor in the meta-analysis. Only the Spanish
cohort showed an association signal but, solely when the rare non-
synonymous variants were pooled with the p.A442 variant, which
was not significant in the single variant analysis, suggesting a false
positive association in the Spanish cohort. This is supported by the
results of themeta-analysis which did not show any association with
rare variants in general in PLD3 and EOAD risk. Amongst the rare
variants identified in the current study, two were novel splice site
variants. One was identified in an AD patient and one in a control
individual. We showed that the splice variant identified in the AD
patient does not lead to NMD because the premature stop codon
is introduced in the last exon of the transcript. Moreover, Schulte
et al. (2015) also reported an exon deletion variant in one control
individual, suggesting that this mechanism may not be related to
AD pathology.
While the current study was in progress, different attempts to
replicate the genetic association of rare variants in PLD3 with
LOAD risk in family-based studies, case–control cohorts, and pop-
ulation cohorts were unsuccessful [Lambert et al., 2015; van der
Lee et al., 2015; Heilmann et al., 2015; Hooli et al., 2015]. Our
data in EOAD cohorts corroborate these negative findings. Of note,
both the p.V232M and the p.A442 variants from the initial study
[Cruchaga et al., 2014]were not associatedwithAD risk in any of the
EOAD cohorts we investigated as well as in the other LOAD stud-
ies [Lambert et al., 2015; van der Lee et al., 2015; Heilmann et al.,
2015; Hooli et al., 2015]. So far, only one study reported a nominal
excess of PLD3 rare variants when EOAD patients were pooled with
LOAD(P = 0.03) but the gene-burden associationwas not significant
when EOADpatients were investigated separately (P = 0.54, n = 139)
[Schulte et al., 2015]. Notably, also in this study, neither p.V232M
nor p.A442 were associated with EOADor LOAD risk [Schulte et al.,
2015]. On the other hand, they identified a silent variant, p.I364,
present exclusively in LOADpatients with aMAFof 1.05% in 15 het-
erozygous and four homozygous carriers that seems to contribute
significantly to the observed association [Schulte et al., 2015]. We
included the EOAD cohort screened by Schulte et al. (2015) in our
HUMANMUTATION, Vol. 36, No. 12, 1226–1235, 2015 1233
Figure 3. PLD3 exon 12 skipping and NMD escape. Representation of PLD3 exon 12 skipping mechanism. Exon counting is based on RefSeq
NM_001031696.3. In Cruchaga et al. (2014), exon 12 corresponds to exon 10. Agarose gel picture (top) shows the results of the exon 11 - 3′UTR
fragments amplification, which was carried out using a primer in exon 11 (5′-ACGAGCGTGGCGTCAAG-3′) [Cruchaga et al., 2014] in combination
with a reverse primer located in the 3′-UTR (5′-GGGGTGGAGGTAGAGGTGGG-3′). The wild-type amplicon is 563 bp in size and in case of exon
12 skipping (100 bp) the expected amplicon length is 463 bp, in case of intron retention the product is 660 bp. The full-length PLD3 cDNA
amplification product is reported (bottom gel). Amplification carried out using forward primer 5′-ATCCCCCAGCCTTGAGGGAAG-3′ and reverse
primer 5′-GGGGTGGAGGTAGAGGTGGG -3′). The wild-type PCR fragment is 1,644 bp and the two additional bands are visible. Electropherograms,
obtained after sequencing of the agarose gel extraction product, show the normal transcript and exon 12 skipping. The longer product shows
retention of intron 12. In the right bottom panel, the splicing mechanism is showed with the production of the three alternative transcripts (a)
wild-type, (b) exon 12 skipping, and (c) longer transcript with intron 12 retention). A blue triangle in the exon 13 of the aberrant transcript indicates
the introduction of a premature termination codon (PTC).
meta-analysis with the European cohorts screened in this study and
overall we did not identify a significant association of rare PLD3
variants when patients were compared with control individuals.
The authors of the original PLD3 association finding in LOAD
[Cruchaga and Goate, 2015a; Cruchaga and Goate, 2015b], at-
tributed the failure of the replication studies [Lambert et al., 2015;
van der Lee et al., 2015; Heilmann et al., 2015] to population stratifi-
cation and/or regional differences in variantMAFs.The latter factors
might have amajor influence in replication studies of low-frequency
variants [Cruchaga and Goate, 2015a]. We indeed noticed that the
appearance andMAFs of rare variants in the different European co-
horts was dissimilar. For example, we did not observe the previously,
nominally associated p.M6Rvariant [Cruchaga et al., 2014] in any of
the cohorts we screened. Nevertheless, each patient/control cohort
in our studywas ethnicallymatched, arguing against a false-negative
finding due to cohort stratification.
In conclusion, our study investigated the role of rare variants
in PLD3 in an extended cohort of European EOAD patient and
matched control individuals that were ascertained in the BELNEU
and EU EOD consortia. Our study was not limited to the rare vari-
ants published [Cruchaga et al., 2014], but included a complete
analysis of the coding region to capture all rare variants in patients
and matched control persons. The negative replication data we ob-
tained were in line with those reported in four studies of LOAD
[Lambert et al., 2015; van der Lee et al., 2015; Heilmann et al., 2015;
Hooli et al., 2015]. Our findings in EOAD, reinforce the notion that
PLD3 unlikely contributes to genetic risk for AD, indifferent of age
of onset of the disease. Moreover, if PLD3 variants were involved in
earlier onset age of AD symptoms, as was suggested in the initial
study, one could expect that a cohort of EOAD patients would be
enriched for these variants compared with LOAD patients. This was
clearly not the case in our studymaking it unlikely that there is a cor-
relation between PLD3 variations and earlier-onset age. Together,
the contradictory data indicate that taken the negative replication
data, we should be careful to attribute a biological role to PLD3 in
AD pathogenesis.
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